Fig. 4.

Simulated profiles of the proportions of patients suffering from any grade of rash (left) or severe rash (right) for the different dosing regimens explained in the legend; “pulse” refers to the weekly pulsed high erlotinib dose (D3–D6 have the pulses administered on two consecutive days every week), and “low” refers to the continuous low dose to be administered daily for the rest of the week (which was not administered in the first week for D3–D6, and therefore assigned with (0) in the legend)